Clinical Trials Recruiting Participants
Sorry, the Clinical Trials ParticipantsRecruiting has finished at this period, we no longer recruit participants untilnew information is released.
    
    
How can we help you?
US CLINICAL TRIALS & CHINA CLINICAL TRIALS
Currently we have one US Phase II Clinical Trial and one China Phase III Clinical Trials enrolling chronic heart failure patients with NYHA Classification II and III.
US CLINICAL TRIALS
Efficacy and Safety of Human Recombination Neuregulin-1 to Treat Stable Chronic Heart Failure (ZS-01-210).
ClinicalTrials.gov Identifier:
NCT01251406
http://clinicaltrials.gov/ct2/show/NCT01251406?term=zensun&rank=3

Detailed Description:
This randomized, parallel, placebo-controlled, double-blind, multi-center study will assess the safety and efficacy of NeucardinTM as a treatment for stable chronic heart failure.
A total of 120 subjects, who have chronic heart failure with a NYHA classification of II or III, and are on a stable regimen of ACEI/angiotensin receptor blocker (ARB), beta-blocker, and/or diuretic for at least 3 months prior to receiving study medication and anticipated to remain on the stable regimen through the treatment period can enroll as per specific inclusion and exclusion criteria.
Subjects will be hospitalized for 10 days during the treatment period and will be infused subcutaneously with rhNRG-1 or placebo. Contacts and Locations.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01251406
CHINA CLINICAL TRIALS
Efficacy and Safety of Human Recombination Neuregulin-1 to Treat Stable Chronic Heart Failure .
SFDA Clinical Trials ID: 2010L00444
For more details, please click the following link:
Contacts
Contact: Luzandra Magana, CCRC
1-619 203-4804
luzandra_magana@zensunusa.com
 
Clinical Trials Recruiting Participants